One qualifier I brought up before is frequency of dosing. This calculation assumes that those treated get a treatment course every year. That may not be the case, and we don’t have data on the durability as yet. But suppose on average the treatment is applied every second year. That would halve the revenue.
I still like those numbers.
Potential Financial Implications of Yesterday's Results, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
44.5¢ |
Change
0.015(3.49%) |
Mkt cap ! $176.8M | |||
| Open | High | Low | Value | Volume |
| 45.0¢ | 45.0¢ | 43.0¢ | $364.9K | 828.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55155 | 43.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 24999 | 2 |
View Market Depth
| Last trade - 16.10pm 08/07/2025 (20 minute delay) ? |
| PAR (ASX) Chart |